Health TidingsTerrestrial Begins First-in-Human Trial of Needle-Free Semaglutide Microarr... Terrestrial Begins First-in-Human Trial of Needle-Free Semaglutide Microarr... Read Post »
Health Tidings Mergers & AcquisitionsIpsen Acquires Memo Therapeutics, Adds Potravitug to Rare Disease Pipeline Ipsen Acquires Memo Therapeutics, Adds Potravitug to Rare Disease Pipeline Read Post »
Health TidingsGalderma Receives FDA Complete Response Letter for Relfydess BLA; Manufactu... Galderma Receives FDA Complete Response Letter for Relfydess BLA; Manufactu... Read Post »
Clinical TrialsCan-Fite Reports Durable Survival with Namodenoson in Heavily Pretreated Pa... Can-Fite Reports Durable Survival with Namodenoson in Heavily Pretreated Pa... Read Post »
Clinical TrialsNew ITC Analyses Support Overall Survival Benefit of Mogamulizumab in CTCL New ITC Analyses Support Overall Survival Benefit of Mogamulizumab in CTCL Read Post »
Health TidingsKowa Submits FDA NDA for Nicox’s NCX 470 in Open-Angle Glaucoma and O... Kowa Submits FDA NDA for Nicox’s NCX 470 in Open-Angle Glaucoma and O... Read Post »
Health TidingsMesoblast Files FDA BLA for Rexlemestrocel-L to Prevent GI Bleeding in LVAD... Mesoblast Files FDA BLA for Rexlemestrocel-L to Prevent GI Bleeding in LVAD... Read Post »
Health TidingsAzurity Acquires CONTRAVE to Expand into Obesity Treatment Azurity Acquires CONTRAVE to Expand into Obesity Treatment Read Post »
Health TidingsFDA Approves Orca Bio’s TREGZI to Improve Chronic GVHD-Free Survival ... FDA Approves Orca Bio’s TREGZI to Improve Chronic GVHD-Free Survival ... Read Post »
Clinical TrialsBeOne’s BRUKINSA Plus Rituximab Cuts Progression Risk by 43% in First-Lin... BeOne’s BRUKINSA Plus Rituximab Cuts Progression Risk by 43% in First-Lin... Read Post »
Clinical TrialsSkyhawk Reports Positive 12-Month Phase 1/2 SKY-0515 Data in HuntingtonR... Skyhawk Reports Positive 12-Month Phase 1/2 SKY-0515 Data in HuntingtonR... Read Post »
Clinical TrialsSanofi’s Nexviazyme Meets All Endpoints in Phase 3 Baby-COMET Study for I... Sanofi’s Nexviazyme Meets All Endpoints in Phase 3 Baby-COMET Study for I... Read Post »
